DCC4578 |
Sampatrilat |
Vasopeptidase or dual inhibitor of ACE and neutral endopeptidase with potential application in the treatment of hypertension and congestive heart failure |
|
DCC4579 |
Sansanmycin |
Uridyl peptide antibiotic, exhibiting antibacterial activity against Mycobacterium tuberculosis H(37)Ra and Pseudomonas aeruginosa with MIC values of 10 and 12.5 mug/ml, respectively |
|
DCC4580 |
Sant-2 |
Novel potent inhibitor of Shh signaling pathway |
|
DCC4581 |
Sap2-in-23h |
Novel Potent Non-peptidic Inhibitor of Secreted Aspartic Protease 2 (SAP2) for the Treatment of Resistant Fungal Infections |
|
DCC4582 |
Saperconazole |
Broad-spectrum antifungal agent, selective inhibiting the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes, in vitro and in vivo activity against F. pedrosoi |
|
DCC4583 |
Sar-104772 |
Novel inhibitor of TAFIa (activated thrombin-activatable fibrinolysis inhibitor) |
|
DCC4584 |
Sar107375 |
Novel selective and potent dual inhibitor of thrombin and factor Xa |
|
DCC4585 |
Sarafloxacin |
Broad spectrum antibiotic |
|
DCC4586 |
Sarcolipin |
Regulator of the sarco-endoplasmic reticulum Ca -ATPase (SERCA1a), significantly slowing down the E2 to Ca2.E1 transition of SERCA1a while it affects neither phosphorylation nor dephosphorylation |
|
DCC4587 |
Sarcolipin Palmitoylated |
Regulator of the sarco-endoplasmic reticulum Ca -ATPase (SERCA1a), significantly slowing down the E2 to Ca2.E1 transition of SERCA1a while it affects neither phosphorylation nor dephosphorylation |
|
DCC4588 |
Sard033 |
Novel Highly Potent Selective Androgen Receptor Degrader (SARD) |
|
DCC4589 |
Sard279 |
Novel Potent Selective Androgen Receptor Degrader (SARD) |
|
DCC4590 |
Sarmustine |
Covalent Antineoplastic Agent |
|
DCC4591 |
Sars-cov 3clpro-in-7d |
Novel potent SARS-CoV-2 3CLpro inhibitor with IC 50 value of 73 nM |
|
DCC4592 |
Sars-cov-2 Mpro Inhibitor E24 |
Novel SARS-CoV-2 Main Protease (Mpro) Inhibitor, inhibiting viral replication with a nanomolar EC 50 value (844 nM) in SARS-CoV-2-infected Vero E6 cells, impairing SARS-CoV-2 replication in human lung epithelial cells and human-induced pluripotent stem ce |
|
DCC4593 |
Sars-cov-2 Nsp14 Mtase Inhibitor 16 |
Novel SARS-CoV-2 nsp14 Methyltransferase inhibitor |
|
DCC4594 |
Sars-cov-2 Nsp14/16 Inhibitor 2a |
Novel potent SARS-CoV-2 MTase Nsp14 and Nsp16 inhibitor |
|
DCC4595 |
Satavaptan |
Selective non-peptide vasopressin V2 receptor antagonist |
|
DCC4596 |
Satavaptan Fumarate |
Selective non-peptide vasopressin V2 receptor antagonist |
|
DCC4597 |
Sat-in-3 |
Novel inhibitor of salmonella serine acetyltransferase (SAT), the enzyme that catalyzes the rate-limiting step of L-cysteine biosynthesis |
|
DCC4598 |
Saussureamine C |
Inhibitor of H274Y and N294S mutants |
|
DCC4599 |
Sazetidine-a Dihydrochloride |
Subtype-selective α4β2 nicotinic acetylcholine receptor partial agonist |
|
DCC4600 |
Sb1404 |
PPARγ covalent ligand |
|
DCC4601 |
Sb1495 |
Novel reversible covalent inhibitor of the cyclin-dependent kinase 5 (Cdk5)-mediated phosphorylation of PPARγ at Ser245, a key factor in the insulin-sensitizing effect of PPARγ-targeted drugs |
|
DCC4602 |
Sb1617 |
Novel neuroprotective agent, suppressing abnormal tau protein aggregation |
|
DCC4603 |
Sb-203347 |
Selective, active-site-directed 14 kDa PLA2 inhibitor, totally inhibiting LT and PAF formation, while prostanoid formation was not altered |
|
DCC4604 |
Sb-209670 |
Dual ETA and ETB receptor antagonist |
|
DCC4605 |
Sb-220025 Trihydrochloride |
Potent, specific inhibitor of human p38 mitogen-activated protein (MAP) kinase |
|
DCC4606 |
Sb-226552 |
Potent and selective agonist for the human ß3-adrenoceptor |
|
DCC4607 |
Sb-239272 |
Inhibitor of p38 MAPK |
|